Certara, a global pioneer in biosimulation, introduces the Non-Animal Navigator™, a purpose-built solution designed to help lab managers reduce reliance on animal testing. This innovation is aligned with the FDA’s strategic push for New Approach Methodologies (NAMs), helping laboratories pivot efficiently in a changing regulatory landscape.
For lab managers balancing timelines, budgets, and ethical mandates, Certara’s solution offers a modular approach to integrate AI-based simulation with traditional preclinical methods. The platform also provides regulatory foresight, ensuring labs remain compliant and scientifically competitive.
Benefits for Lab Managers:
- Enhance Compliance: Meet evolving FDA and EMA standards with future-ready strategies.
- Optimize Resources: Reduce animal study costs and complexity.
- Speed Up Development: Leverage AI-driven biosimulation for faster decision-making.
- Strengthen Predictive Evidence: Improve clinical translation with validated QSP models.
- Align Cross-Functional Teams: Coordinate toxicologists, regulators, and developers seamlessly.
Certara’s Non-Animal Navigator™ empowers labs to lead with innovation, ensuring ethical and operational readiness in a transforming industry.
This article has been sourced from a press release and may include content created or refined using AI tools and verified by our editorial team. For the full press release, visit: "Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing."
